Q-omics provides the consensus-scored NPIPB11 profile across patient tissues and cancer cell-line models. NPIPB11 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NPIPB11 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, NPIPB11 RNA expression shows 15,587 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where NPIPB11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NPIPB11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NPIPB11 survival associations across molecular data types. NPIPB11 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NPIPB11 RNA expression–survival associations across cancer types. High NPIPB11 expression shows unfavorable associations in KIRC, COAD and PRAD, but favorable associations in BLCA, HNSC and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NPIPB11 RNA expression.
This table summarizes NPIPB11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NPIPB11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NPIPB11 shows higher tumor expression in KIRC, KIRP, HNSC, STAD, KICH and COAD. The KIRC box plot shows higher NPIPB11 RNA expression in tumor versus normal tissue (log2 FC = +0.369, t-test p < 0.001).
This table shows molecular features associated with NPIPB11 in patient tissues and cancer cell lines. In patient samples, NPIPB11 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, NPIPB11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia.
